CorMedix announces publication of taurolidine pre-clinical oncology data
CorMedix announced publication of in vitro and in vivo pre-clinical data demonstrating taurolidine's effective anti-tumor properties in pediatric neuroblastoma. The paper, entitled: "Dual Functionality of the Antimicrobial Agent Taurolidine which Demonstrates Effective Anti-tumor Properties in Pediatric Neuroblastoma" appears in the July 2019 edition of Investigational New Drugs, a peer-review journal that provides a forum for the rapid dissemination of information on new anti-cancer agents. The study investigated the in vitro activity of taurolidine against neuroblastoma using the alamar blue cytotoxicity assay, phase-contrast light microscopy, western blotting, and analysis of global gene expression by RNA-Seq. In vivo activity of taurolidine was evaluated using mouse xenograft models. The study's findings support the further investigation and evaluation of taurolidine in future pre-clinical studies and clinical trials for the treatment of pediatric neuroblastoma. Neuroblastoma is the most common extracranial solid tumor and one of the most complex and difficult-to-treat diseases in pediatric patients. The study was led by Dr. Aru Narendran, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, with CorMedix providing financial support.